IMSTAR sponsor of the 14th International Workshop on Radiation Damage to DNA (IWRDD), Melbourne, Australia, March 20-24th, 2016

Mar20

Prof. Michael Fenech (Professor and Director of Genome Health and Personalised Nutrition Laboratory, CSIRO Adelaïde, Australia) presented a conference at the Biomarker Session, focused on the CBMN assay and state-of-the-Art in its automation, including illustration of IMSTAR’s Pathfinder capacities, notably for radiation biodosimetry purposes, of high content analysis, in which multiple biomarkers in the CBMN assay (MN, NPB etc.) are measured simultaneously with molecular markers such as γH2AX, centromeres activity, etc.)

Read more IWRDD Abstract – Michael Fenech

MEDUSA, an EU ITEA2 Innovation Project terminate end December 2015

Jan02

IMSTAR is partner in the European ITEA2 Innovation project MEDUSA: Medical Distributed Utilization of Services & Applications (period 15/12/2012 to 31/12/2015), that groups 14 industrial partners, technology companies and hospitals in France and the Netherlands.

Within this project, IMSTAR developed an innovative concept, based on its proprietary Pathfinder™ platform to enable Virtualised imaging environment and service-based hosted solution for in vitro early diagnosis and treatment in oncology.

The design of a truly successful solution requires that specialized legacy applications and their associated data can be access from the newly developed cloud environment, giving the same level of collaboration and accessibility from anywhere as all the new innovative applications. MEDUSA solutions, concepts, tools and architectures are developed from that vision. The expected results can immediately be applied to the cloud based medical application products of the future and thus give Europe a strategic advantage in this world-wide new field.

MEDUSA aims to provide a new service concept by introducing:

1. Advanced imaging as a service, by which MEDUSA

  • Ensures the efficient exchange of medical information while satisfying the high levels of safety, security and privacy required for such a secure environment;
  • Supports and encourages the appropriate use of both remote and local advanced medical image processing in real-time, such that the medical professional obtains the required level of detail of information;
  • Supports transparency with respect to geographical location, both fixed and mobile.

2. Secure virtual workspaces as a service, by which MEDUSA

  • Supports a collaborative workspace in a professional medical situation, where knowledge, capabilities and patient data are brought together and made available for clinical processing, respecting medical regulations and clinical procedures and protocols. This is an area where traceability, latency and interoperability are crucial issues;

3. Medical diagnosis support as a service, by which MEDUSA:

  • Enables physicians to virtually group around a patient for diagnosis and treatment decision making;

To find out more, please visit web site: https://itea3.org/project/medusa.html

IMSTAR, proud sponsor of two international meetings on “The next 3 decades of the Comet assay” and “DNA stability in occupational biomonitoring”

Sep30

IMSTAR is a pioneer in the field of cell analysis for Life Sciences research and assisted In Vitro Diagnostic (IVD), providing innovative concepts in digital image cytometry and quantitative analysis through its proprietary Pathfinder™ technology.
The Company services clients in the fields of digital cyto-histopathology, cytogenetic and environmental mutagenesis and genetic toxicity, applied to a large range of tests for preclinical research, tumor biomarkers validation in assisted IVD, bio-monitoring and compounds screening, amongst others.

International Comet Assay Workshop (ICAW 2015)

Antwerp, Belgium, September 5th, 2015 – This symposium deals with practical and theoretical aspects of the Comet Assay, aimed at both experienced and new users of this popular technique. As part of the week long manifestation, IMSTAR provided a Comet Assays Hands-On Training session, demonstrating the accessibility and accuracy of their proprietary Pathfinder™ ScreenTox™ AutoComet fully automated scoring system.
“For the past 20 years, we have worked with leaders in the field of in vitro/in vivo genotoxicity testing and DNA damage assessment, aiming to advance the state of the art of automated comet assay analysis”, said Françoise Soussaline, IMSTAR CEO and CSO. The use of IMSTAR’s PathfinderTM fully-automated system allows not only the scoring of several-fold higher number of cells, as demonstrated in recent studies, but an improved accuracy and robustness for the test. An increased sensitivity of in vitro comet assay could be particularly important for biomonitoring studies where small differences in DNA damage levels could be relevant”.

Read more: http://www.imstarsa.com/wp-content/uploads/2015/09/Mutation-Research-749-2012-70%E2%80%93-75_Sharma-et-al.pdf

First International Symposium on the Impact of Occupational Exposures on DNA Stability and Human Cancer Risks

Graz, Austria, September 12th, 2015 – Millions of humans are currently exposed to chemicals and other factors which affect the stability of the genetic material and/or cause cancer and other long term toxic effects. To protect this part of the population, strong efforts have been made to monitor and reduce the risks of these harmful factors; nevertheless, biomonitoring represents still a tremendous challenge in terms of expertise, method and cost.
Françoise Soussaline, speaker in this symposium, presented a methodological approach in cytogenetic quantitative analysis and DNA damage evaluation for human biomonitoring using automated high-throughput high-content Image Cytometry, with the aim to assess the impact of nutrition, chemicals and radiation on genomic stability and other health related processes.

For more information, please contact:
IMSTAR S.A.
93 boulevard Arago
Paris 75014, France
Tel: +33 (0)1 42 34 93 70
Fax: +33 (0)1 46 34 51 57

Sidebar